FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Ator

Research Profile

Concepts & Ideas

Living Beings

Chemicals & Drugs

Procedures

Anatomy

Tumor Cell Line

Co-author Network

Publications

TOP 3
Derek Dunn; Rita Raddatz; Mark A Ator; Edward R Bacon; Sankar Chatterjee
From an atypical wake-promoting agent to potent histamine-3 receptor inverse agonists.
Lisa Saville; Chrysanthe Spais; Jennifer L Mason; Sheryl L Meyer; Seetha Murthy; Albom Mark; Thelma S Angeles; Mark A Ator; Jean Husten
Time-resolved fluorescence resonance energy transfer as a versatile tool in the development of homogeneous cellular kinase assays.
Jennifer L Mason; Sheryl L Meyer; Eric Prouty; Chrysanthe Spais; Albom Mark; Mark A Ator; Jean Husten; Thelma S Angeles
Comparison of LanthaScreen Eu kinase binding assay and surface plasmon resonance method in elucidating the binding kinetics of focal adhesion kinase inhibitors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Ator (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Derek Dunn; Rita Raddatz; Mark A Ator; Edward R Bacon; Sankar Chatterjee
From an atypical wake-promoting agent to potent histamine-3 receptor inverse agonists.
Chemical biology & drug design 2013;81(3):433-5.
2012: Lisa Saville; Chrysanthe Spais; Jennifer L Mason; Sheryl L Meyer; Seetha Murthy; Albom Mark; Thelma S Angeles; Mark A Ator; Jean Husten
Time-resolved fluorescence resonance energy transfer as a versatile tool in the development of homogeneous cellular kinase assays.
Assay and drug development technologies 2012;10(6):551-7.
2012: Jennifer L Mason; Sheryl L Meyer; Eric Prouty; Chrysanthe Spais; Albom Mark; Mark A Ator; Jean Husten; Thelma S Angeles
Comparison of LanthaScreen Eu kinase binding assay and surface plasmon resonance method in elucidating the binding kinetics of focal adhesion kinase inhibitors.
Assay and drug development technologies 2012;10(5):468-75.
2012: Benjamin J Dugan; Diane E Gingrich; Zeqi Huang; Mahfuza Jan; Jennifer L Mason; Eugen F Mesaros; Sheryl L Meyer; Karen L Milkiewicz; Bruce Ruggeri; Cynthia Serdikoff; Kevin J Wells-Knecht; Allison L Zulli; Lisa D Aimone; Albom Mark; Thelma S Angeles; Mark A Ator; Matthew A Curry; Pawel Dobrzanski; Bruce D Dorsey
A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779.
Journal of medicinal chemistry 2012;55(11):5243-54.
2012: Derek Dunn; John Gruner; Greg Hostetler; Mohamed Iqbal; Bruce Jones; Yin-Guo Lin; Val R Marcy; Lisa D Aimone; Mark A Ator; Edward R Bacon; Sankar Chatterjee
Wake promoting agents: search for next generation modafinil, lessons learned: part III.
Bioorganic & medicinal chemistry letters 2012;22(11):3751-3.
2012: Diane E Gingrich; R Curtis Haltiwanger; Joseph G Lisko; Lihui Lu; Gregory R Ott; Matthew Quail; Bruce Ruggeri; Weihua Wan; Kevin Wells-Knecht; Lisa D Aimone; Albom Mark; Thelma S Angeles; Mark A Ator; Mangeng Cheng; Matthew A Curry; Arup K Ghose; Bruce D Dorsey
Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.
Journal of medicinal chemistry 2012;55(10):4580-93.
2012: Derek Dunn; Jean Husten; Mohamed Iqbal; Mark A Ator; S Chatterjee
Serendipity in discovery of proteasome inhibitors.
Bioorganic & medicinal chemistry letters 2012;22(10):3503-5.
2012: Mohamed Iqbal; SK Mallya; Patricia A Messina McLaughlin; Mark A Ator; Derek Dunn; Jean Husten; S Chatterjee
Proteasome inhibitors for cancer therapy.
Bioorganic & medicinal chemistry 2012;20(7):2362-8.
2012: Joyce James; Susan Jones-Bolin; Ronald R Nepomuceno; Martin W Rowbottom; Bruce Ruggeri; Michael Williams; Mehran Yazdanian; Hugh Zhao; Julius L Apuy; Robert C Armstrong; Mark A Ator; Shripad S Bhagwat; Mangeng Cheng; Merryl D Cramer; Pawel Dobrzanski; Bruce D Dorsey; Raffaella Faraoni; Michael F Gardner; Dana Gitnick; Ruwanthi N Gunawardane; Kathryn Hunter; Darren E Insko; Mark W Holladay
CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.
Molecular cancer therapeutics 2012;11(4):930-41.
2012: Jie Qian; Mark A Ator; Beverly P Holskin; Jennifer L Mason; Sheryl L Meyer; Kristen A Murray; Thelma S Angeles
Comparison of two homogeneous cell-based kinase assays for JAK2 V617F: SureFire pSTAT5 and GeneBLAzer fluorescence resonance energy transfer assays.
Assay and drug development technologies 2012;10(2):212-7.
2012: Derek Dunn; John Gruner; Greg Hostetler; Mohamed Iqbal; Yin-Guo Lin; Patricia Messina-McLaughlin; Alyssa Reiboldt; Mark A Ator; Edward R Bacon; Sankar Chatterjee
Wake-promoting agents: search for next generation modafinil: part II.
Bioorganic & medicinal chemistry letters 2012;22(6):2315-7.
2012: Derek Dunn; John Gruner; Greg Hostetler; Mohamed Iqbal; Yin-Guo Lin; Patricia Messina-McLaughlin; Alyssa Reiboldt; Mark A Ator; Edward R Bacon; Sankar Chatterjee
Wake-promoting agents: search for next generation modafinil: part I.
Bioorganic & medicinal chemistry letters 2012;22(6):2312-4.
2012: Mangeng Cheng; Flavio Cristofani; Bruce D Dorsey; Diane E Gingrich; Giorgio Inghirami; Lihui Lu; Rodolfo Machiorlatti; Gregory R Ott; Matthew R Quail; Cristina Abele; Lisa D Aimone; Albom Mark; Thelma S Angeles; Mark A Ator; Weihua Wan; Bruce A Ruggeri
CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Molecular cancer therapeutics 2012;11(3):670-9.
2012: Robert L Hudkins; Kathryn Hunter; Susan Jones-Bolin; John Mallamo; Sheila J Miknyoczki; Lisa D Aimone; Albom Mark; Thelma S Angeles; Mark A Ator; Edward R Bacon; Nadine C Becknell; Hong Chang; Ted L Underiner; Hugh Zhao; Allison L Zulli; Bruce Ruggeri
Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent.
Journal of medicinal chemistry 2012;55(2):903-13.
2011: Kevin J Wells-Knecht; Mehran Yazdanian; Kelli Zeigler; Lisa D Aimone; Mark A Ator; Henry J Breslin; Mangeng Cheng; Diane E Gingrich; Zeqi Huang; Eugen F Mesaros; Gregory R Ott; Linda Weinberg; Gregory J Wells; Bruce D Dorsey
2,7-Disubstituted-pyrrolotriazine kinase inhibitors with an unusually high degree of reactive metabolite formation.
Chemical research in toxicology 2011;24(11):1994-2003.
2011: Lily D Lu; Jennifer L Mason; Bruce A Ruggeri; Mark S Albom; Thelma S Angeles; Mark A Ator; Pawel Dobrzanski; Bruce D Dorsey; Benjamin J Dugan; Diane E Gingrich; Cynthia Serdikoff; Kristine L Stump; Nate H Wallace; Matthew M Seavey
Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2.
Journal of immunology (Baltimore, Md. : 1950) 2011;187(7):3840-53.
2011: Gregory R Ott; Matthew R Quail; Bruce Ruggeri; Tho V Thieu; Weihua Wan; Gregory J Wells; Lisa D Aimone; Albom Mark; Thelma S Angeles; Mark A Ator; Mangeng Cheng; Arup K Ghose; Diane E Gingrich; Zeqi Huang; Joseph G Lisko; Lihui Lu; Eugen F Mesaros; Bruce D Dorsey
2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity.
Journal of medicinal chemistry 2011;54(18):6328-41.
2011: Mark W Holladay; Andiliy G Lai; Martin W Rowbottom; Bruce R Ruggeri; Eduardo Setti; Kelly G Sprankle; Lan Tran; Michael Williams; Sunny Abraham; Robert C Armstrong; Mark A Ator; Shripad S Bhagwat; Brian T Campbell; Qi Chao; Merryl D Cramer; Bruce D Dorsey; Raffaella Faraoni; Michael F Gardner; Dana Gitnick; Ruwanthi N Gunawardane; Joyce James
4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors.
Bioorganic & medicinal chemistry letters 2011;21(18):5342-6.
2011: Robert L Hudkins; Lars J S Knutsen; John Mallamo; Michael J Marino; Joanne R Mathiasen; Gilbert Moachon; Catherine P Prouty; Rita Raddatz; Ming Tao; Lisa D Aimone; Mark A Ator; Edward R Bacon; Nadine C Becknell; Mehran Yazdanian; Michael Williams
Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
Journal of medicinal chemistry 2011;54(13):4781-92.
2011: Kristine L Stump; Cynthia Serdikoff; Albom Mark; Thelma S Angeles; Mark A Ator; Pawel Dobrzanski; Bruce D Dorsey; Ben J Dugan; Diane E Gingrich; Lily D Lu; Bruce A Ruggeri; Matthew M Seavey
A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.
Arthritis research & therapy 2011;13(2):R68.
2008: Bruce D Dorsey; Mohamed Iqbal; Sankar Chatterjee; Ernesto Menta; Raffaella Bernardini; A Bernareggi; Paolo G Cassarà; Germano D'Arasmo; Edmondo Ferretti; Sergio De Munari; Ambrogio Oliva; Gabriella Pezzoni; Cecilia Allievi; Ivan Strepponi; Bruce Ruggeri; Mark A Ator; Michael Williams; John Mallamo
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
Journal of medicinal chemistry 2008;51(4):1068-72.
2007: Sheila J Miknyoczki; Hong Chang; Jennifer Grobelny; Sonya Pritchard; Candace Worrell; Natalie McGann; Mark A Ator; Jean Husten; James Deibold; Robert L Hudkins; Allison Zulli; Ralph E Parchment; Bruce Ruggeri
The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.
Molecular cancer therapeutics 2007;6(8):2290-302.
2007: Derek Dunn; Jean Husten; Mark A Ator; Sankar Chatterjee
Novel poly(ADP-ribose) polymerase-1 inhibitors.
Bioorganic & medicinal chemistry letters 2007;17(2):542-5.
2006: Mark A Ator; John Mallamo; Michael Williams
Overview of drug discovery and development.
Current protocols in pharmacology / editorial board, S.J. Enna (editor-in-chief) ... [et al.] 2006;Chapter 9():Unit9.9.
2006: Gregory J Wells; Ron Bihovsky; Robert L Hudkins; Mark A Ator; Jean Husten
Synthesis and structure-activity relationships of novel pyrrolocarbazole lactam analogs as potent and cell-permeable inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).
Bioorganic & medicinal chemistry letters 2006;16(5):1151-5.
2006: Ming Tao; Chung Ho Park; Ron Bihovsky; Gregory J Wells; Jean Husten; Mark A Ator; Robert L Hudkins
Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors.
Bioorganic & medicinal chemistry letters 2006;16(4):938-42.
2006: Weihua Wan; Albom Mark; Lihui Lu; Matthew R Quail; Nadine C Becknell; Linda R Weinberg; Dandu R Reddy; Beverly P Holskin; Thelma S Angeles; Ted L Underiner; Sheryl L Meyer; Robert L Hudkins; Bruce D Dorsey; Mark A Ator; Bruce Ruggeri; Mangeng Cheng
Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells.
Blood 2006;107(4):1617-23.
2004: John T Durkin; Beverly P Holskin; Karla K Kopec; Matt S Reed; Chrysanthe M Spais; Brian M Steffy; George W Gessner; Thelma S Angeles; Jan Pohl; Mark A Ator; Sheryl L Meyer
Phosphoregulation of mixed-lineage kinase 1 activity by multiple phosphorylation in the activation loop.
Biochemistry 2004;43(51):16348-55.
2003: Diane E Gingrich; Dandu R Reddy; Mohamed A Iqbal; Jasbir Singh; Lisa D Aimone; Thelma S Angeles; Albom Mark; Shi Yang; Mark A Ator; Sheryl L Meyer; Candy Robinson; Bruce Ruggeri; Craig Dionne; Jeffry L Vaught; John Mallamo; Robert L Hudkins
A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
Journal of medicinal chemistry 2003;46(25):5375-88.
2003: Bruce Ruggeri; Jasbir Singh; Diane E Gingrich; Thelma S Angeles; Albom Mark; Shi Yang; Hong Chang; Candy Robinson; Kathryn Hunter; Pawel Dobrzanski; Susan Jones-Bolin; Sonya Pritchard; Lisa D Aimone; Andres Klein-Szanto; Jean-Marc Herbert; Francoise Bono; Paul Schaeffer; Pierre Casellas; Bernard Bourie; Roberto Pili; John T Isaacs; Mark A Ator; Robert L Hudkins; Jeffry L Vaught; John Mallamo; Craig Dionne
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Cancer research 2003;63(18):5978-91.
2003: Sheila J Miknyoczki; Susan Jones-Bolin; Sonya Pritchard; Kathryn Hunter; Hugh Zhao; Weihua Wan; Mark A Ator; Ronald Bihovsky; Robert L Hudkins; Sankar Chatterjee; Andres Klein-Szanto; Craig Dionne; Bruce Ruggeri
Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
Molecular cancer therapeutics 2003;2(4):371-82.
2002: Chikara Murakata; Masami Kaneko; George W Gessner; Thelma S Angeles; Mark A Ator; Teresa M O'Kane; Beth Ann W McKenna; Beth Ann Thomas; Joanne R Mathiasen; Michael Saporito; Donna Bozyczko-Coyne; Robert L Hudkins
Mixed lineage kinase activity of indolocarbazole analogues.
Bioorganic & medicinal chemistry letters 2002;12(2):147-50.
2000: Rabindranath Tripathy; Mark A Ator; John Mallamo
Calpain inhibitors based on the quiescent affinity label concept: high rates of calpain inactivation with leaving groups derived from N-hydroxy peptide coupling reagents.
Bioorganic & medicinal chemistry letters 2000;10(20):2315-9.
1999: S Chatterjee; Derek Dunn; SK Mallya; Mark A Ator
P'-extended alpha-ketoamide inhibitors of proteasome.
Bioorganic & medicinal chemistry letters 1999;9(17):2603-6.
1999: S Chatterjee; Derek Dunn; Ming Tao; G Wells; ZQ Gu; Ron Bihovsky; Mark A Ator; R Siman; John Mallamo
P2-achiral, P'-extended alpha-ketoamide inhibitors of calpain I.
Bioorganic & medicinal chemistry letters 1999;9(16):2371-4.
1998: Rabindranath Tripathy; ZQ Gu; Derek Dunn; SE Senadhi; Mark A Ator; S Chatterjee
P2-proline-derived inhibitors of calpain I.
Bioorganic & medicinal chemistry letters 1998;8(19):2647-52.
1998: SK Mallya; S Meyer; Donna Bozyczko-Coyne; R Siman; Mark A Ator
A sensitive, continuously recording fluorogenic assay for calpain.
Biochemical and biophysical research communications 1998;248(2):293-6.
1998: S Chatterjee; ZQ Gu; Derek Dunn; Ming Tao; KA Josef; Rabindranath Tripathy; Ron Bihovsky; SE Senadhi; Teresa M O'Kane; Beth Ann W McKenna; SK Mallya; Mark A Ator; Donna Bozyczko-Coyne; R Siman; John Mallamo
D-amino acid containing, high-affinity inhibitors of recombinant human calpain I.
Journal of medicinal chemistry 1998;41(15):2663-6.
1997: S Chatterjee; Mark A Ator; Donna Bozyczko-Coyne; KA Josef; G Wells; Rabindranath Tripathy; Mohamed Iqbal; Ron Bihovsky; SE Senadhi; SK Mallya; Teresa M O'Kane; Beth Ann W McKenna; R Siman; John Mallamo
Synthesis and biological activity of a series of potent fluoromethyl ketone inhibitors of recombinant human calpain I.
Journal of medicinal chemistry 1997;40(23):3820-8.